Jennison Associates
DFTX

Jennison Associates’s Definium Therapeutics DFTX Stock Holding History

Jennison Associates’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$755K Sell
39,957
-13,828
-26% -$235K ﹤0.01% 520
2025
Q4 		$720K Buy
+53,785
New +$666K ﹤0.01% 535

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates's DFTX Position: Q1 2026 in Review

Jennison Associates reduced its Definium Therapeutics (DFTX) stake by 26% in Q1 2026, selling an estimated $235K and leaving 39,957 shares worth $755K. The position accounts for ﹤0.01% of the portfolio, ranked #520.

Jennison Associates first reported a position in DFTX in Q4 2025 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Jennison Associates held 39,957 shares of Definium Therapeutics worth $755K as of Q1 2026.
  • Jennison Associates sold 13,828 Definium Therapeutics shares in Q1 2026, an estimated $235K.
  • Definium Therapeutics made up ﹤0.01% of Jennison Associates's portfolio in Q1 2026, its #520 holding.
  • Jennison Associates first reported a position in Definium Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.